Skip to main content

Table 2 Laboratory results of the study groups

From: Combined value of left ventricular ejection fraction and the Model for End-Stage Liver Disease (MELD) score for predicting mortality in patients with acute coronary syndrome who were undergoing percutaneous coronary intervention

Variable Survivors (n = 663) Non-survivors (n = 183) P value
Peak-troponin-Ia, ng/mL 28 (19–44) 30 (18–51) 0.444a
Peak-troponin-I*, ng/mL 1.8 (0.6–4.2) 2.3 (0.5–12.4) 0.853b
Total cholesterol 170 ± 40 179 ± 46 0.128
SCr* adm (mg/dl) 0.82 (0.73–1.02) 1.03 (0.79–1.42) < 0.001
WBC (× 103/mm3) 11 ± 3 12 ± 4 < 0.001
Hemoglobin (g/dl) 12.6 ± 2 11.8 ± 2.2 < 0.001
LVEF (%) 47.5 ± 10.0 41.3 ± 11.8 < 0.001
ALT* (U/L) 32 (21–49) 28 (18–54) 0.420
AST* (U/L) 51 (27–105) 44 (23–129) 0.321
Total bilirubin* (mg/dl) 0.57 (0.40 ± 0.78) 0.60 (0.40–0.90) 0.015
INR 1 ± 0.11 1 ± 0.16 < 0.001
MELD score 7.8 ± 2.4 10.1 ± 4.4 <  0.001
  1. SCr serum creatinine at admission, WBC wight blood cell, LVEF left ventricular ejection fraction, ALT alanine transaminase, AST aspartat transaminase, INR international normalised ratio, MELD model for liver end-stage liver disease
  2. *Comparison was made using Mann-Whitney U test at P < 0.05, and these values were described by median with inter-quartile range (25th and 75th percentile)
  3. aComparison was made in patients with ST-elevation myocardial infarction
  4. bComparison was made in patients with non-ST-elevation myocardial infarction